XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.20.2

Reportable Segment Information (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2020
Segment Reporting [Abstract] |
Summary of Financial Information for Each Reportable Segment | The following table presents various financial information for each reportable segment for the three and nine months ended June 30, 2020 and 2019.
| Three months ended |  |  | Nine months ended |
| June 30 |  |  | June 30 |
(In millions - unaudited) | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
SALES |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 189 |  |  | $ | 190 |  |  | $ | 528 |  |  | $ | 556 |
Personal Care & Household |  | 155 |  |  |  | 158 |  |  |  | 451 |  |  |  | 495 |
Consumer Specialties |  | 344 |  |  |  | 348 |  |  |  | 979 |  |  |  | 1,051 |
Specialty Additives |  | 135 |  |  |  | 177 |  |  |  | 429 |  |  |  | 494 |
Performance Adhesives |  | 70 |  |  |  | 88 |  |  |  | 229 |  |  |  | 258 |
Industrial Specialties |  | 205 |  |  |  | 265 |  |  |  | 658 |  |  |  | 752 |
Intermediates and Solvents |  | 37 |  |  |  | 41 |  |  |  | 102 |  |  |  | 118 |
Intersegment sales (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intermediates and Solvents |  | (12 | ) |  |  | (13 | ) |  |  | (22 | ) |  |  | (37 | )
| $ | 574 |  |  | $ | 641 |  |  | $ | 1,717 |  |  | $ | 1,884 |
OPERATING INCOME (LOSS) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 40 |  |  | $ | 32 |  |  | $ | 97 |  |  | $ | 88 |
Personal Care & Household |  | 16 |  |  |  | 17 |  |  |  | (309 | ) |  |  | 60 |
Consumer Specialties |  | 56 |  |  |  | 49 |  |  |  | (212 | ) |  |  | 148 |
Specialty Additives |  | 15 |  |  |  | 19 |  |  |  | (137 | ) |  |  | (5 | )
Performance Adhesives |  | 13 |  |  |  | 16 |  |  |  | 40 |  |  |  | 42 |
Industrial Specialties |  | 28 |  |  |  | 35 |  |  |  | (97 | ) |  |  | 37 |
Intermediates and Solvents |  | 7 |  |  |  | 8 |  |  |  | (7 | ) |  |  | 20 |
Unallocated and other |  | (43 | ) |  |  | (49 | ) |  |  | (87 | ) |  |  | (125 | )
| $ | 48 |  |  | $ | 43 |  |  | $ | (403 | ) |  | $ | 80 |
DEPRECIATION EXPENSE |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 8 |  |  | $ | 8 |  |  | $ | 24 |  |  | $ | 24 |
Personal Care & Household |  | 10 |  |  |  | 10 |  |  |  | 30 |  |  |  | 30 |
Consumer Specialties |  | 18 |  |  |  | 18 |  |  |  | 54 |  |  |  | 54 |
Specialty Additives |  | 15 |  |  |  | 15 |  |  |  | 46 |  |  |  | 84 |
Performance Adhesives |  | 4 |  |  |  | 4 |  |  |  | 10 |  |  |  | 11 |
Industrial Specialties |  | 19 |  |  |  | 19 |  |  |  | 56 |  |  |  | 95 |
Intermediates and Solvents |  | 4 |  |  |  | 3 |  |  |  | 10 |  |  |  | 8 |
Unallocated and other |  | — |  |  |  | — |  |  |  | — |  |  |  | 3 |
| $ | 41 |  |  | $ | 40 |  |  | $ | 120 |  |  | $ | 160 |
AMORTIZATION EXPENSE |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 7 |  |  | $ | 7 |  |  | $ | 21 |  |  | $ | 21 |
Personal Care & Household |  | 9 |  |  |  | 10 |  |  |  | 27 |  |  |  | 28 |
Consumer Specialties |  | 16 |  |  |  | 17 |  |  |  | 48 |  |  |  | 49 |
Specialty Additives |  | 5 |  |  |  | 5 |  |  |  | 14 |  |  |  | 14 |
Performance Adhesives |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 1 |
Industrial Specialties |  | 5 |  |  |  | 5 |  |  |  | 15 |  |  |  | 15 |
Intermediates and Solvents |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |
| $ | 21 |  |  | $ | 22 |  |  | $ | 63 |  |  | $ | 65 |
EBITDA (b) (c) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences | $ | 55 |  |  | $ | 47 |  |  | $ | 142 |  |  | $ | 133 |
Personal Care & Household |  | 35 |  |  |  | 37 |  |  |  | (252 | ) |  |  | 118 |
Consumer Specialties |  | 90 |  |  |  | 84 |  |  |  | (110 | ) |  |  | 251 |
Specialty Additives |  | 35 |  |  |  | 39 |  |  |  | (77 | ) |  |  | 93 |
Performance Adhesives |  | 17 |  |  |  | 20 |  |  |  | 51 |  |  |  | 54 |
Industrial Specialties |  | 52 |  |  |  | 59 |  |  |  | (26 | ) |  |  | 147 |
Intermediates and Solvents |  | 11 |  |  |  | 11 |  |  |  | 3 |  |  |  | 29 |
Unallocated and other |  | (43 | ) |  |  | (49 | ) |  |  | (83 | ) |  |  | (122 | )
| $ | 110 |  |  | $ | 105 |  |  | $ | (216 | ) |  | $ | 305 |
|  |  |  |  |  |  |  |  | June 30, 2020 |  |  | September 30, 2019 |
TOTAL ASSETS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Life Sciences |  |  |  |  |  |  |  |  | $ | 1,979 |  |  | $ | 1,946 |
Personal Care & Household |  |  |  |  |  |  |  |  |  | 979 |  |  |  | 1,366 |
Consumer Specialties |  |  |  |  |  |  |  |  |  | 2,958 |  |  |  | 3,312 |
Specialty Additives |  |  |  |  |  |  |  |  |  | 1,642 |  |  |  | 1,775 |
Performance Adhesives |  |  |  |  |  |  |  |  |  | 595 |  |  |  | 618 |
Industrial Specialties |  |  |  |  |  |  |  |  |  | 2,237 |  |  |  | 2,393 |
Intermediates and Solvents |  |  |  |  |  |  |  |  |  | 164 |  |  |  | 185 |
Unallocated and other |  |  |  |  |  |  |  |  |  | 1,627 |  |  |  | 1,361 |
|  |  |  |  |  |  |  |  | $ | 6,986 |  |  | $ | 7,251 |
| (a) | Intersegment sales from Intermediates and Solvents are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
| (b) | Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
| (c) | Includes $39 million of accelerated depreciation for the nine months ended June 30, 2019.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration